Baumann S

No ORCID on file · 2 papers in corpus · active 2022-2025

Study types

  • rct 1

Condition tags

  • endometriosis 1
2025
Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study.
Pharmaceuticals (Basel, Switzerland) ·doi:10.3390/ph18050758

Background/Objectives: P2X3 receptor antagonists have been suggested as a potential treatment for urogenital, respiratory and pain conditions. This first-in-human (FiH) study evaluated filapixant, a new P2X3 receptor antagonist with high re…

rct 2022
First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
British journal of clinical pharmacology ·doi:10.1111/bcp.15358

AIMS: Neuronal hypersensitisation due to adenosine triphosphate-dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first-in-human study of eliapixant (BAY 1817080…